Market Overview

Verona Pharma plc ("Verona" or the "Company") Appointment of Nominated Adviser and UK Broker

Share:

LONDON, May 01, 2019 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (NASDAQ:VRNA) ("Verona Pharma"), a clinical stage biopharmaceutical company focused on respiratory diseases, is pleased to announce the appointment of Nplus1 Singer Advisory LLP (together with its associates, "N+1 Singer") as nominated adviser and UK corporate broker to the Company with immediate effect.

For further information contact:

Verona Pharma plc
Jan-Anders Karlsson, Chief Executive Officer
Victoria Stewart, Director of Communications
 
Tel: +44 (0)20 3283 4200
info@veronapharma.com

 
N+1 Singer (Nominated Adviser and UK Broker)
Aubrey Powell /Jen Boorer /Iqra Amin (Corporate Finance)
Mia Gardner (Corporate Broking)
Tel: +44 (0)20 7496 3000
   
ICR, Inc. (US Media and Investor enquiries)
Darcie Robinson

Stephanie Carrington
Tel: +1 203-919-7905
Darcie.Robinson@icrinc.com
Tel. +1 646-277-1282
Stephanie.Carrington@icrinc.com

About Verona Pharma plc

Verona Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for the treatment of respiratory diseases with significant unmet medical needs. Verona Pharma's product candidate, ensifentrine (RPL554), is a first-in-class, inhaled, dual inhibitor of the enzymes phosphodiesterase 3 and 4 that has been shown to act as both a bronchodilator and an anti-inflammatory agent in a single compound. Ensifentrine is currently in Phase 2b clinical development for the maintenance treatment of COPD and is planned to enter Phase 3 trials for this indication in 2020. Verona Pharma is also developing ensifentrine for the treatment of cystic fibrosis and asthma.

Verona.jpg

View Comments and Join the Discussion!
 
Lightning Fast
Market News Service
$199 Free 14 Day Trial